Mga Batayang Estadistika
| CIK | 1822929 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Eucrates Biomedical Acquisition Corp
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File No. 001-39650 EUCRATES BIOMEDICAL ACQUISITION CORP. (Exact name of registrant as sp |
|
| April 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-396 |
|
| April 11, 2023 |
Eucrates Biomedical Acquisition Corp. Announces Liquidation Exhibit 99.1 Eucrates Biomedical Acquisition Corp. Announces Liquidation New York, April 11, 2023 — Eucrates Biomedical Acquisition Corp. (Nasdaq: EUCR) (the “Company”) announced the following today: ● The Company anticipates that it will not be able to consummate an initial business combination within the time period required by its Amended and Restated Memorandum and Articles of Association. ● A |
|
| April 11, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 7, 2023 Eucrates Biomedical Acquisition Corp. (Exact name of registrant as specified in its charter) British Virgin Islands 001-39650 N/A (State or other jurisdiction (Commissio |
|
| April 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 30, 2023 Eucrates Biomedical Acquisition Corp. (Exact name of registrant as specified in its charter) British Virgin Islands 001-39650 N/A (State or other jurisdiction (Commissi |
|
| March 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-CEN ¨ Form N-CSR For Period Ended: December 31, 2022 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form 10-Q For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| February 16, 2023 |
Promissory Note, dated February 15, 2023 Exhibit 10.1 THIS PROMISSORY NOTE (“NOTE”) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE SALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY DE |
|
| February 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 15, 2023 Eucrates Biomedical Acquisition Corp. (Exact name of registrant as specified in its charter) British Virgin Islands 001-39650 N/A (State or other jurisdiction (Commi |
|
| February 10, 2023 |
VG:EUCR / Eucrates Biomedical Acquisition Corp / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| November 14, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001- |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 7, 2022 Eucrates Biomedical Acquisition Corp. (Exact name of registrant as specified in its charter) British Virgin Islands 001-39650 N/A (State or other jurisdiction (Commis |
|
| October 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 25, 2022 Eucrates Biomedical Acquisition Corp. (Exact name of registrant as specified in its charter) British Virgin Islands 001-39650 N/A (State or other jurisdiction (Commis |
|
| October 31, 2022 |
Amendment to the Amended and Restated Memorandum and Articles of Association Exhibit 3.1 Territory of the British Virgin Islands The BVI Business Companies Act, 2004 MEMORANDUM AND ARTICLES OF ASSOCIATION OF Eucrates Biomedical Acquisition Corp. Incorporated as a BVI Business Company on 21 August 2020 Amended and Restated on 22 October 2020 and on 25 October 2022 1 TERRITORY OF THE BRITISH VIRGIN ISLANDS THE BVI BUSINESS COMPANIES ACT 2004 MEMORANDUM OF ASSOCIATION OF EUCR |
|
| October 24, 2022 |
Regulation FD Disclosure, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 24, 2022 Eucrates Biomedical Acquisition Corp. (Exact name of registrant as specified in its charter) British Virgin Islands 001-39650 N/A (State or other jurisdiction (Commis |
|
| October 12, 2022 |
DEF 14A 1 tm2226828d4def14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only ( |
|
| October 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defi |
|
| October 5, 2022 |
EUCRATES BIOMEDICAL ACQUISITION CORP. 250 West 55th Street, Suite 13D New York, New York 10019 EUCRATES BIOMEDICAL ACQUISITION CORP. 250 West 55th Street, Suite 13D New York, New York 10019 October 5, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Real Estate & Construction 100 F Street, N.E. Washington, D.C. 20549 Attention: Ruairi Regan and Brigitte Lippmann Re: Eucrates Biomedical Acquisition Corp. Preliminary Proxy Statement on Schedule |
|
| September 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| August 15, 2022 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 23, 2022 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-CEN ¨ Form N-CSR For Period Ended: March 31, 2022 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 11-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 10-Q For the Transition Perio |
|
| April 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-396 |
|
| March 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-CEN ¨ Form N-CSR For Period Ended: December 31, 2021 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form 10-Q For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| January 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 20, 2022 Eucrates Biomedical Acquisition Corp. (Exact name of registrant as specified in its charter) British Virgin Islands 001-39650 N/A (State or other jurisdiction (Commis |
|
| January 26, 2022 |
Exhibit 10.2 THIS PROMISSORY NOTE (?NOTE?) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE SALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY DE |
|
| December 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 10-K/A 1 tm2135789d110ka.htm FORM 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 2) (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition pe |
|
| November 22, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 15, 2021 Eucrates Biomedical Acquisition Corp. (Exact name of registrant as specified in its charter) British Virgin Islands 001-39650 N/A (State or other jurisdiction (Commi |
|
| November 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-CEN ¨ Form N-CSR For Period Ended: September 30, 2021 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form 10-Q For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| August 16, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-39650 EUCRATES BIOMEDI |
|
| July 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-3 |
|
| June 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 17, 2021 Eucrates Biomedical Acquisition Corp. (Exact name of registrant as specified in its charter) British Virgin Islands 001-39650 N/A (State or other jurisdiction of incorpo |
|
| June 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 1, 2021 (May 28, 2021) Eucrates Biomedical Acquisition Corp. (Exact name of registrant as specified in its charter) British Virgin Islands 001-39650 N/A (State or other jurisdict |
|
| June 1, 2021 |
EXHIBIT 99.1 EUCRATES BIOMEDICAL ACQUISITION CORP. RECEIVES EXPECTED NOTICE FROM NASDAQ REGARDING DELAYED QUARTERLY REPORT New York, NY, June 1, 2021/PRNewswire/ ? Eucrates Biomedical Acquisition Corp. (Nasdaq: EUCR) (the ?Company?), a special purpose acquisition company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar busin |
|
| May 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ? Form 10-K ? Form 20-F ? Form 11-K x Form 10-Q ? Form 10-D ? Form N-CEN ? Form N-CSR For Period Ended: March 31, 2021 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| March 31, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-39650 EUCRATES BIOMED |
|
| March 31, 2021 |
Exhibit 4.5 EUCRATES BIOMEDICAL ACQUISITION CORP. DESCRIPTION OF SECURITIES We are a company incorporated in the British Virgin Islands as a BVI business company (company number 2042314) and our affairs are governed by our memorandum and articles of association, the Companies Act and the common law of the British Virgin Islands. We are authorized to issue an unlimited number of both ordinary share |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Eucrates Biomedical Acquisition Corp. (Name of Issuer) Ordinary shares, no par value (Title of Class of Securities) G3141W106 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| December 14, 2020 |
Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 14, 2020 Eucrates Biomedical Acquisition Corp. (Exact name of registrant as specified in its charter) British Virgin Islands 001-39650 N/A (State or other jurisdiction (Commi |
|
| December 14, 2020 |
EUCRATES BIOMEDICAL Acquisition Corp. Exhibit 99.1 EUCRATES BIOMEDICAL Acquisition Corp. Announces the Separate Trading of its ORDINARY SHARES and Redeemable Warrants NEW YORK, NY, December 14, 2020 - Eucrates Biomedical Acquisition Corp. (the “Company”), a special purpose acquisition company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination |
|
| December 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-39650 EUCRATES BIO |
|
| November 30, 2020 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 24, 2020 Eucrates Biomedical Acquisition Corp. (Exact name of registrant as specified in its charter) British Virgin Islands 001-39650 N/A (State or other jurisdiction (Commi |
|
| November 30, 2020 |
EUCRATES BIOMEDICAL ACQUISITION CORPORATION BALANCE SHEET OCTOBER 27, 2020 Exhibit 99.1 EUCRATES BIOMEDICAL ACQUISITION CORPORATION BALANCE SHEET OCTOBER 27, 2020 October 27, 2020 Pro Forma Adjustments As Adjusted (unaudited) (unaudited) ASSETS Current assets Cash $ 711,200 $ — $ 711,200 Prepaid expenses and other current assets 520,400 — 520,400 Total Current Assets 1,231,600 — 1,231,600 Cash held in Trust Account 100,000,000 4,796,260 104,796,260 Total Assets $ 101,231 |
|
| November 2, 2020 |
Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 27, 2020 Eucrates Biomedical Acquisition Corp. (Exact name of registrant as specified in its charter) British Virgin Islands 001-39650 N/A (State or other jurisdiction (Commis |
|
| November 2, 2020 |
EUCRATES BIOMEDICAL ACQUISITION CORP. Index to Financial Statement Exhibit 99.1 EUCRATES BIOMEDICAL ACQUISITION CORP. Index to Financial Statement Report of Independent Registered Public Accounting Firm F-2 Balance Sheet F-3 Notes to Financial Statement F-4 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Shareholders and the Board of Directors of Eucrates Biomedical Acquisition Corp. Opinion on the Financial Statement We have audited the accompanyi |
|
| October 30, 2020 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| October 28, 2020 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is entered into as of October 23, 2020, by and among Eucrates Biomedical Acquisition Corp., a British Virgin Islands company (the “Company”), Eucrates LLC (the “Investor”) and any other holder of Registrable Securities (as defined below) which becomes a party to this Agreement pursuant to Section 6.2. |
|
| October 28, 2020 |
Indemnity Agreement, dated October 23, 2020, between the Company and William Campbell. Exhibit 10.12 INDEMNITY AGREEMENT THIS INDEMNITY AGREEMENT (this “Agreement”) is made as of October 23, 2020, by and between EUCRATES BIOMEDICAL ACQUISITION CORP., a British Virgin Islands business company organized with limited liability (the “Company”), and William Campbell (“Indemnitee”). RECITALS WHEREAS, highly competent persons have become more reluctant to serve publicly-held corporations a |
|
| October 28, 2020 |
Indemnity Agreement, dated October 23, 2020, between the Company and Daphne Karydas. Exhibit 10.11 INDEMNITY AGREEMENT THIS INDEMNITY AGREEMENT (this “Agreement”) is made as of October 23, 2020, by and between EUCRATES BIOMEDICAL ACQUISITION CORP., a British Virgin Islands business company organized with limited liability (the “Company”), and Daphne Karydas (“Indemnitee”). RECITALS WHEREAS, highly competent persons have become more reluctant to serve publicly-held corporations as |
|
| October 28, 2020 |
Indemnity Agreement, dated October 23, 2020, between the Company and Stelios Papadopoulos. EX-10.5 9 tm2034386d1ex10-5.htm EXHIBIT 10.5 Exhibit 10.5 INDEMNITY AGREEMENT THIS INDEMNITY AGREEMENT (this “Agreement”) is made as of October 23, 2020, by and between EUCRATES BIOMEDICAL ACQUISITION CORP., a British Virgin Islands business company organized with limited liability (the “Company”), and Stelios Papadopoulos (“Indemnitee”). RECITALS WHEREAS, highly competent persons have become more |
|
| October 28, 2020 |
Indemnity Agreement, dated October 23, 2020, between the Company and Parag Saxena. Exhibit 10.6 INDEMNITY AGREEMENT THIS INDEMNITY AGREEMENT (this “Agreement”) is made as of October 23, 2020, by and between EUCRATES BIOMEDICAL ACQUISITION CORP., a British Virgin Islands business company organized with limited liability (the “Company”), and Parag Saxena (“Indemnitee”). RECITALS WHEREAS, highly competent persons have become more reluctant to serve publicly-held corporations as off |
|
| October 28, 2020 |
Indemnity Agreement, dated October 23, 2020, between the Company and Evangelos Vergetis. Exhibit 10.7 INDEMNITY AGREEMENT THIS INDEMNITY AGREEMENT (this “Agreement”) is made as of October 23, 2020, by and between EUCRATES BIOMEDICAL ACQUISITION CORP., a British Virgin Islands business company organized with limited liability (the “Company”), and Evangelos Vergetis (“Indemnitee”). RECITALS WHEREAS, highly competent persons have become more reluctant to serve publicly-held corporations |
|
| October 28, 2020 |
Underwriting Agreement, dated October 23, 2020, by and between the Company and the Representatives. Exhibit 1.1 EUCRATES BIOMEDICAL ACQUISITION CORP. 10,000,000 Units Units, each consisting of one (1) ordinary share, no par value, and one-third of one warrant Underwriting Agreement October 23, 2020 Underwriting Agreement October 23, 2020 Stifel, Nicolaus & Company, Incorporated H.C. Wainwright & Co., LLC as representatives of the Underwriters c/o Stifel, Nicolaus & Company, Incorporated 1 South |
|
| October 28, 2020 |
Indemnity Agreement, dated October 23, 2020, between the Company and Amitabh Singhal. Exhibit 10.14 INDEMNITY AGREEMENT THIS INDEMNITY AGREEMENT (this “Agreement”) is made as of October 23, 2020, by and between EUCRATES BIOMEDICAL ACQUISITION CORP., a British Virgin Islands business company organized with limited liability (the “Company”), and Amitabh Singhal (“Indemnitee”). RECITALS WHEREAS, highly competent persons have become more reluctant to serve publicly-held corporations as |
|
| October 28, 2020 |
Exhibit 10.1 INVESTMENT MANAGEMENT TRUST AGREEMENT This Investment Management Trust Agreement (this “Agreement”) is made as of October 23, 2020 by and between Eucrates Biomedical Acquisition Corporation (the “Company”) and Continental Stock Transfer & Trust Company (the “Trustee”). WHEREAS, the Company’s registration statement on Form S-1, No. 333-249333 (“Registration Statement”) and prospectus ( |
|
| October 28, 2020 |
Exhibit 4.1 WARRANT AGREEMENT This Warrant Agreement (this “Agreement”) made as of October 23, 2020 between Eucrates Biomedical Acquisition Corp., a British Virgin Islands company, with offices at 250 West 55th Street, New York, NY 10019 (“Company”), and Continental Stock Transfer& Trust Company, a New York corporation, with offices at One State Street, 30th Floor, New York, New York 10004 (“Warra |
|
| October 28, 2020 |
Exhibit 99.2 EUCRATES BIOMEDICAL Acquisition Corp. Announces CLOSING of $100 Million Initial Public Offering NEW YORK, NY, October 27, 2020 - Eucrates Biomedical Acquisition Corp. (the “Company”), a special purpose acquisition company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more busi |
|
| October 28, 2020 |
Indemnity Agreement, dated October 23, 2020, between the Company and Shrikant Sathe. Exhibit 10.9 INDEMNITY AGREEMENT THIS INDEMNITY AGREEMENT (this “Agreement”) is made as of October 23, 2020, by and between EUCRATES BIOMEDICAL ACQUISITION CORP., a British Virgin Islands business company organized with limited liability (the “Company”), and Shrikant Sathe (“Indemnitee”). RECITALS WHEREAS, highly competent persons have become more reluctant to serve publicly-held corporations as o |
|
| October 28, 2020 |
Exhibit 10.4 UNIT SUBSCRIPTION AGREEMENT This UNIT SUBSCRIPTION AGREEMENT (this “Agreement”) is made as of this 23rd day of October, 2020, by and between Eucrates Biomedical Acquisition Corp., a company incorporated in the British Virgin Islands with number 2042314 (the “Company”), having its principal place of business at 250 West 55th Street, Suite 13D, New York, New York 10019, and Eucrates LLC |
|
| October 28, 2020 |
Indemnity Agreement, dated October 23, 2020, between the Company and Atanuu Agarrwal. Exhibit 10.10 INDEMNITY AGREEMENT THIS INDEMNITY AGREEMENT (this “Agreement”) is made as of October 23, 2020, by and between EUCRATES BIOMEDICAL ACQUISITION CORP., a British Virgin Islands business company organized with limited liability (the “Company”), and Atanuu Agarrwal (“Indemnitee”). RECITALS WHEREAS, highly competent persons have become more reluctant to serve publicly-held corporations as |
|
| October 28, 2020 |
Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 23, 2020 Eucrates Biomedical Acquisition Corp. (Exact name of registrant as specified in its charter) British Virgin Islands 001-39650 N/A (State or other jurisdiction (Commis |
|
| October 28, 2020 |
Exhibit 99.1 EUCRATES BIOMEDICAL Acquisition Corp. Announces Pricing of $100 Million Initial Public Offering NEW YORK, NY, October 23, 2020 - Eucrates Biomedical Acquisition Corp. (the “Company”), a special purpose acquisition company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more busi |
|
| October 28, 2020 |
Indemnity Agreement, dated October 23, 2020, between the Company and Nina Shapiro. Exhibit 10.13 INDEMNITY AGREEMENT THIS INDEMNITY AGREEMENT (this “Agreement”) is made as of October 23, 2020, by and between EUCRATES BIOMEDICAL ACQUISITION CORP., a British Virgin Islands business company organized with limited liability (the “Company”), and Nina Shapiro (“Indemnitee”). RECITALS WHEREAS, highly competent persons have become more reluctant to serve publicly-held corporations as of |
|
| October 28, 2020 |
Exhibit 10.3 October 23, 2020 Eucrates Biomedical Acquisition Corp. 250 West 55th Street, Suite 13D New York, NY 10019 Parag Saxena, Chief Executive Officer Stifel, Nicolaus & Company, Incorporated 1 South Street, 15th Floor Baltimore, Maryland 21202 Attn: Syndicate Fax No.: (443) 224-1273 H.C. Wainwright & Co., LLC 430 Park Avenue, 3rd Floor New York, New York 10022 Attn: Richard Gormley, Vice Ch |
|
| October 28, 2020 |
Indemnity Agreement, dated October 23, 2020, between the Company and Gonzalo Cordova. Exhibit 10.8 INDEMNITY AGREEMENT THIS INDEMNITY AGREEMENT (this “Agreement”) is made as of October 23, 2020, by and between EUCRATES BIOMEDICAL ACQUISITION CORP., a British Virgin Islands business company organized with limited liability (the “Company”), and Gonzalo Cordova (“Indemnitee”). RECITALS WHEREAS, highly competent persons have become more reluctant to serve publicly-held corporations as |
|
| October 28, 2020 |
EX-3.1 3 tm2034386d1ex3-1.htm EXHIBIT 3.1 Exhibit 3.1 TERRITORY OF THE BRITISH VIRGIN ISLANDS THE BVI BUSINESS COMPANIES ACT 2004 MEMORANDUM OF ASSOCIATION OF EUCRATES BIOMEDICAL ACQUISITION CORP. a company limited by shares Amended and restated on 22 October 2020 1 NAME The name of the Company is Eucrates Biomedical Acquisition Corp.. 2 STATUS The Company shall be a company limited by shares. 3 R |
|
| October 26, 2020 |
$100,000,000 Eucrates Biomedical Acquisition Corp. 10,000,000 Units TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(4) Registration No. 333-249333 PROSPECTUS $100,000,000 Eucrates Biomedical Acquisition Corp. 10,000,000 Units Eucrates Biomedical Acquisition Corp. is a blank check company incorporated in the British Virgin Islands as a business company and formed for the purpose of acquiring, engaging in a share exchange, share reconstruction and amalgamation wit |
|
| October 22, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF l934 Eucrates Biomedical Acquisition Corp. (Exact name of Registrant as specified in its charter) British Virgin Islands N/A (State of incorporation or organization) (I.R.S. Employer Identification No.) |
|
| October 21, 2020 |
EUCRATES BIOMEDICAL ACQUISITION CORP. 250 West 55th Street, Suite 13D New York, New York 10019 October 21, 2020 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-13628 Attention: Sergio Chinos Re: Eucrates Biomedical Acquisition Corp. Registration Statement on Form S-1 (File No. 333-249333) Acceleration Request: Req |
|
| October 21, 2020 |
TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on October 21, 2020 under the Securities Act of 1933, as amended. Registration No. 333-249333 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Eucrates Biomedical Acquisition Corp. (Exact name of registrant as specifi |
|
| October 21, 2020 |
October 21, 2020 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| October 21, 2020 |
Proskauer Rose LLP Eleven Times Square New York, NY 10036-8299 October 21, 2020 Daniel Forman Partner d 212. |
|
| October 15, 2020 |
Exhibit 4.2 Share certificate Number of certificate Number of shares EUCRATES BIOMEDICAL ACQUISITION CORP. Company number 2042314 (COMPANY) INCORPORATED UNDER THE BVI BUSINESS COMPANY ACT, 2004, AS AMENDED This is to certify that of is the registered holder of ordinary shares of no par value each being fully paid in the above-named company, subject to the memorandum and articles of association of |
|
| October 15, 2020 |
Exhibit 10.6 INDEMNITY AGREEMENT THIS INDEMNITY AGREEMENT (this “Agreement”) is made as of [], 2020, by and between EUCRATES BIOMEDICAL ACQUISITION CORP., a British Virgin Islands business company organized with limited liability (the “Company”), and (“Indemnitee”). RECITALS WHEREAS, highly competent persons have become more reluctant to serve publicly-held corporations as officers and/or director |
|
| October 15, 2020 |
Exhibit 10.5 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is entered into as of [], 2020, by and among Eucrates Biomedical Acquisition Corp., a British Virgin Islands company (the “Company”), Eucrates LLC (the “Investor”) and any other holder of Registrable Securities (as defined below) which becomes a party to this Agreement pursuant to Section 6.2. WHEREAS, |
|
| October 15, 2020 |
Exhibit 10.2 INVESTMENT MANAGEMENT TRUST AGREEMENT This Investment Management Trust Agreement (this “Agreement”) is made as of [ ], 2020 by and between Eucrates Biomedical Acquisition Corporation (the “Company”) and Continental Stock Transfer & Trust Company (the “Trustee”). WHEREAS, the Company’s registration statement on Form S-1, No. 333-249333 (“Registration Statement”) and prospectus (the “Pr |
|
| October 15, 2020 |
Form of Amended and Restated Memorandum and Articles of Association* Exhibit 3.2 TERRITORY OF THE BRITISH VIRGIN ISLANDS THE BVI BUSINESS COMPANIES ACT 2004 MEMORANDUM OF ASSOCIATION OF EUCRATES BIOMEDICAL ACQUISITION CORP. a company limited by shares Amended and restated on [.] 1 NAME The name of the Company is Eucrates Biomedical Acquisition Corp.. 2 STATUS The Company shall be a company limited by shares. 3 REGISTERED OFFICE AND REGISTERED AGENT 3.1 The first re |
|
| October 15, 2020 |
Exhibit 4.1 NUMBER U- UNITS SEE REVERSE FOR CERTAIN DEFINITIONS EUCRATES BIOMEDICAL ACQUISITION CORP. CUSIP UNITS CONSISTING OF ONE ORDINARY SHARE AND ONE-THIRD OF ONE WARRANT, EACH WHOLE WARRANT ENTITLING THE HOLDER TO PURCHASE ONE SHARE OF CLASS A COMMON STOCK THIS CERTIFIES THAT is the owner of Units. Each Unit (“Unit”) consists of one (1) ordinary share, no par value per share, of EUCRATES ACQ |
|
| October 15, 2020 |
Form of Warrant Agreement between Continental Stock Transfer & Trust Company and the Registrant.* [Exhibit 4.4] WARRANT AGREEMENT This Warrant Agreement (this “Agreement”) made as of [], 2020 between Eucrates Biomedical Acquisition Corp., a British Virgin Islands company, with offices at 250 West 55th Street, New York, NY 10019 (“Company”), and Continental Stock Transfer& Trust Company, a New York corporation, with offices at One State Street, 30th Floor, New York, New York 10004 (“Warrant Age |
|
| October 15, 2020 |
Exhibit 99.1 EUCRATES BIOMEDICAL ACQUISITION CORP. CHARTER OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS 1. STATUS The Audit Committee (the “Committee”) is a committee of the Board of Directors (the “Board”) of Eucrates Biomedical Acquisition Corp. (the “Company”). 2. PURPOSE The Committee is appointed by the Board for the primary purposes of: · Performing the Board’s oversight responsibilities |
|
| October 15, 2020 |
Memorandum and Articles of Association* Exhibit 3.1 Territory of the British Virgin Islands The BVI Business Companies Act, 2004 memorandum and articles of association OF EUCRATES BIOMEDICAL ACQUISITION CORP. Incorporated as a BVI Business Company on 21 August 2020 TERRITORY OF THE BRITISH VIRGIN ISLANDS THE BVI BUSINESS COMPANIES ACT 2004 MEMORANDUM OF ASSOCIATION OF EUCRATES BIOMEDICAL ACQUISITION CORP. a company limited by shares 1 N |
|
| October 15, 2020 |
Unit Purchase Agreement between the Registrant and the Sponsor* Exhibit 10.4 UNIT SUBSCRIPTION AGREEMENT This UNIT SUBSCRIPTION AGREEMENT (this “Agreement”) is made as of this [●] day of [●], 2020, by and between Eucrates Biomedical Acquisition Corp., a company incorporated in the British Virgin Islands with number 2042314 (the “Company”), having its principal place of business at 250 West 55th Street, Suite 13D, New York, New York 10019, and Eucrates LLC (the |
|
| October 15, 2020 |
EXHIBIT 4.3 Form of Warrant Certificate [FACE] Number Warrants THIS WARRANT SHALL BE NULL AND VOID IF NOT EXERCISED PRIOR TO THE EXPIRATION OF THE EXERCISE PERIOD PROVIDED FOR IN THE WARRANT AGREEMENT DESCRIBED BELOW Eucrates Biomedical Acquisition Corp. Incorporated Under the Laws of the British Virgin Islands CUSIP [•] Warrant Certificate This Warrant Certificate certifies that , or registered a |
|
| October 15, 2020 |
Exhibit 14 CODE OF ETHICS OF EUCRATES BIOMEDICAL ACQUISITION CORP. 1. Introduction The Board of Directors (the “Board”) of Eucrates Biomedical Acquisition Corp. (the “Company”) has adopted this code of ethics (this “Code”), as amended from time to time by the Board and which is applicable to all directors, officers and employees of, and consultants and advisors to, the Company, to: · promote hones |
|
| October 15, 2020 |
Form of Underwriting Agreement* Exhibit 1.1 EUCRATES BIOMEDICAL ACQUISITION CORP. 10,000,000 Units Units, each consisting of one (1) ordinary share, no par value, and one-third of one warrant Underwriting Agreement October [●], 2020 Underwriting Agreement October [●], 2020 Stifel, Nicolaus & Company, Incorporated H.C. Wainwright & Co., LLC as representatives of the Underwriters c/o Stifel, Nicolaus & Company, Incorporated 1 Sout |
|
| October 15, 2020 |
TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on October 15, 2020 under the Securities Act of 1933, as amended. Registration No. 333-249333 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Eucrates Biomedical Acquisition Corp. (Exact name of registrant as specifi |
|
| October 15, 2020 |
Securities Purchase Agreement between the Company and the Sponsor* Exhibit 10.3 Eucrates Biomedical Acquisition Corp. 250 West 55th Street New York, New York 10019 August 25, 2020 Eucrates LLC 250 West 55th Street New York, New York 10019 RE: Securities Purchase Agreement Ladies and Gentlemen: We are pleased to accept the offer you (the “Subscriber”) have made to purchase an aggregate of 2,875,000 ordinary shares (the “Shares”) of no par value per share (the “Ord |
|
| October 15, 2020 |
Exhibit 10.1 [], 2020 Eucrates Biomedical Acquisition Corp. 250 West 55th Street, Suite 13D New York, NY 10019 Parag Saxena, Chief Executive Officer Stifel, Nicolaus & Company, Incorporated [Address] Attn: [] Fax No. [] H.C. Wainwright & Co., LLC [Address] Attn: [] Fax No. [] Re: Initial Public Offering Gentlemen: This letter is being delivered to you in accordance with the Underwriting Agreement |
|
| October 15, 2020 |
Compensation Committee Charter* Exhibit 99.2 EUCRATES BIOMEDICAL ACQUISITION CORP. COMPENSATION COMMITTEE CHARTER The following Compensation Committee Charter (the “Charter”) was adopted by the Board of Directors (the “Board”) of Eucrates Biomedical Acquisition Corp., a British Virgin Islands company (the “Company”). 1. Members. The Board shall appoint the members of the Compensation Committee (the “Committee”). The Committee sh |
|
| October 6, 2020 |
Exhibit 99.3 CONSENT OF WILLIAM I. CAMPBELL As required by Rule 438 under the Securities Act of 1933, as amended, the undersigned hereby consents to being named as a Director Nominee in the Registration Statement on Form S-1 of Eucrates Biomedical Acquisition Corp. (the “Company”), originally filed on October 2, 2020, and any and all amendments thereto, registering securities for issuance in the C |
|
| October 6, 2020 |
Exhibit 99.5 CONSENT OF AMITABH SINGHAL As required by Rule 438 under the Securities Act of 1933, as amended, the undersigned hereby consents to being named as a Director Nominee in the Registration Statement on Form S-1 of Eucrates Biomedical Acquisition Corp. (the “Company”), originally filed on October 2, 2020, and any and all amendments thereto, registering securities for issuance in the Compa |
|
| October 6, 2020 |
TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on October 5, 2020 under the Securities Act of 1933, as amended. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Eucrates Biomedical Acquisition Corp. (Exact name of registrant as specified in its charter) Br |
|
| October 6, 2020 |
Exhibit 99.4 CONSENT OF NINA SHAPIRO As required by Rule 438 under the Securities Act of 1933, as amended, the undersigned hereby consents to being named as a Director Nominee in the Registration Statement on Form S-1 of Eucrates Biomedical Acquisition Corp. (the “Company”), originally filed on October 2, 2020, and any and all amendments thereto, registering securities for issuance in the Company’ |
|
| October 5, 2020 |
CORRESP 1 filename1.htm Proskauer Rose LLP Eleven Times Square New York, NY 10036-8299 October 5, 2020 Daniel Forman Partner d 212.969.3096 f 212.969.2900 [email protected] www.proskauer.com VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3628 Attention: Sergio Chinos Re: Eucrates Biomedical Acquisition Corp. Draft Reg |
|
| September 2, 2020 |
TABLE OF CONTENTS As submitted confidentially with the U.S. Securities and Exchange Commission on September 1, 2020. This draft registration statement has not been publicly filed with the U.S. Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGIST |
